Plutus Capital Management Acquires 7.75% Stake in Ganga Pharmaceuticals Through Warrant Conversion

1 min read Updated on 05 Aug 2025, 04:15 PM

Reviewed by

Jubin VScanX News Team

Overview

Plutus Capital Management LLP has acquired a 7.75% stake in Ganga Pharmaceuticals through warrant conversion. The non-promoter entity acquired 3,75,000 shares via preferential allotment on July 17, 2025. This acquisition increased Ganga Pharmaceuticals' equity share capital from Rs. 4,83,65,000 to Rs. 5,91,15,000. Plutus Capital made the necessary disclosures under SEBI regulations on July 31, 2025.

*this image is generated using AI for illustrative purposes only.

Ganga Pharmaceuticals has seen a significant change in its shareholding structure as Plutus Capital Management LLP acquired a substantial stake in the company through a warrant conversion.

Acquisition Details

Plutus Capital Management LLP, a non-promoter entity, has acquired a 7.75% stake in Ganga Pharmaceuticals. The acquisition was completed through the conversion of convertible warrants into equity shares. Here are the key details of the transaction:

Shares Acquired: 3,75,000
Mode of Acquisition: Preferential allotment
Date of Allotment: July 17, 2025
Percentage Stake: 7.75% of the total share capital (6.34% of the diluted share capital)

Impact on Share Capital

The acquisition has led to an increase in Ganga Pharmaceuticals' equity share capital:

Description	Value
Before Acquisition	Rs. 4,83,65,000 (48,36,500 shares)
After Acquisition	Rs. 5,91,15,000 (59,11,500 shares)

Disclosure and Compliance

In compliance with SEBI regulations, Plutus Capital Management LLP has made the necessary disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The disclosure was filed on July 31, 2025, providing details of the acquisition to both BSE Limited and Ganga Pharmaceuticals.

About the Acquirer

Plutus Capital Management LLP, represented by Siddhant Kabra (DIN: 07470463), is not part of the promoter group of Ganga Pharmaceuticals. Prior to this transaction, Plutus Capital held no shares in the company.

Market Information

Ganga Pharmaceuticals' shares are listed on BSE Limited. Investors and market participants are advised to take note of this significant change in the company's shareholding pattern.

This acquisition marks a notable development for Ganga Pharmaceuticals, potentially influencing its future strategic decisions and market perception.

Historical Stock Returns for Ganga Pharmaceuticals